Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals is a premier biotechnology company that invents, develops, and commercializes treatments for severe medical conditions across ophthalmology, immunology, and oncology. The business generates revenue through direct commercial sales of proprietary medicines like Eylea, collaboration revenues and royalties—most notably alongside Sanofi for Dupixent—and contract manufacturing. Its competitive position is anchored by its proprietary VelociSuite technology platforms, which drive a productive in-house drug discovery engine and sustain a deep clinical pipeline.

Following a peak in 2021 when revenue reached 16.1B and net income touched 8.1B, top-line performance normalized before mounting a steady recovery from 12.2B in 2022 to 14.3B in 2025. Bottom-line results demonstrated similar stability, with net income rising from 4.0B in 2023 to 4.4B in 2024 and 4.5B in 2025. Operating cash flow expanded from 4.4B in 2024 to 5.0B in 2025, which helped lift total cash balances to 3.1B by year-end.

Key strengths include the ongoing label expansion and volume growth of Dupixent, paired with reliable operating cash generation that fully self-funds heavy research and development investments. Conversely, the company faces notable risks from looming patent expirations, biosimilar competition against standard Eylea, and binary clinical trial outcomes across earlier-stage assets. Going forward, the primary areas to watch are the commercial market-share defense of high-dose Eylea and regulatory progress across its emerging oncology pipeline.